Tobira Says Secondary Endpoint In NASH Will Carry CVC Into Pivotal Study

The biotech argues that success in reducing fibrosis is more important than the failed primary endpoint measuring NAFLD activity score improvement – and also meets FDA's expectations – but the firm is taking a beating nonetheless.